Randomised clinical trials are the gold standard for testing the effectiveness of clinical interventions. However, increasing complexity and associated costs may limit their application in the investigation of key cardiovascular knowledge gaps such as the re-evaluation of generic pharmacotherapies. The registry-based randomised clinical trial (RRCT) leverages data sampling from nationwide quality registries to facilitate high participant inclusion rates at comparably low costs and, therefore, may offer a mechanism by which such clinical questions may be answered. To date, a number of studies have been conducted using such trial designs, but uncritical use of the RRCT design may lead to erroneous conclusions. The current review provides insights into the strengths and weaknesses of the RRCT, as well as provides an exploratory example of how a trial may be designed to test the long-term effectiveness of beta blockers in patients with myocardial infarction who have preserved left ventricular systolic function.
Registry-based randomised clinical trial: efficient evaluation of generic pharmacotherapies in the contemporary era

AbstRAct
Randomised clinical trials are the gold standard for testing the effectiveness of clinical interventions. However, increasing complexity and associated costs may limit their application in the investigation of key cardiovascular knowledge gaps such as the re-evaluation of generic pharmacotherapies. The registry-based randomised clinical trial (RRCT) leverages data sampling from nationwide quality registries to facilitate high participant inclusion rates at comparably low costs and, therefore, may offer a mechanism by which such clinical questions may be answered. To date, a number of studies have been conducted using such trial designs, but uncritical use of the RRCT design may lead to erroneous conclusions. The current review provides insights into the strengths and weaknesses of the RRCT, as well as provides an exploratory example of how a trial may be designed to test the long-term effectiveness of beta blockers in patients with myocardial infarction who have preserved left ventricular systolic function.
IntRoductIon
From small-scale investigations in the mid-20th century until the emergence of megatrials in the 1980s, 1 the randomised clinical trial (RCT) has become the gold standard for clinical hypothesis testing and, therefore, the evaluation of the effectiveness of interventions. The key feature of the RCT is its ability, through random selection, to clarify proof of treatment effects by minimising selection bias and influence from known and unknown confounders.
Yet the design and implementation of clinically relevant RCTs may be hindered by a number of factors. The primary concern is the increasing cost of clinical trials to bring new drugs to market. 2 Factors that influence these costs are, among others, the disease specifics, incidence of events to be prevented and the necessary trial infrastructure (multicentre studies being more expensive). Given the potential lack of return of investment, any evaluation of generic pharmacotherapies in a contemporary population is unlikely to be undertaken by industry. Additionally, excessive legislative and administrative elements present barriers to the conduct of RCTs. 3 In an attempt to overcome these barriers, new RCT designs have been proposed that use data from quality registries. [4] [5] [6] [7] The cohort multiple RCT and the cluster RCT are two such methodologies, but as yet have not been widely applied. 4 8 The registry-based randomised clinical trial (RRCT) also leverages data from registries and has been shown to rapidly recruit participants at a low overall study cost while maintaining high scientific quality.
In this review, we describe the RRCT concept, using the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) as an example of a national quality registry. We provide an example of how an RRCT may be designed to test the effectiveness of a generic pharmacotherapy, beta-adrenoceptor blockers (beta blockers), after acute myocardial infarction (MI) among patients without heart failure or left ventricular systolic dysfunction. We also discuss how the uncritical use of registry data in clinical trials may overlook important observations, which may affect trial outcome. As such, the aim of this review is to enable readers to judge the quality of a registry for use in an RRCT and thereby critically appraise trials based on this concept.
RRct desIgn ApplIed In clInIcAl tRIAls to dAte
Whereas registries have been used in RCTs for some time, to our knowledge it was only in 2010 that the term 'registry-based randomised clinical trial' was first used. 9 Prior to this, registries were employed to track longer term outcomes within an RCT framework, but did not have full integration of the trial within a registry. 10 Using a strategy containing either 'registry-based' or 'register based' and 'randomized' or 'randomised' trial (see online supplementary appendix for details), we searched PubMed and Embase for manuscripts published concerning completed RRCTs or methodological descriptions of ongoing RRCTs. In total, we found 161 publications, and after review of the abstracts identified 10 RRCTs that reported the collection of baseline and follow-up data from registries (see table 1 ). Of these, we found that the majority of completed RRCTs used the SWEDE-HEART registry for data collection. In general, the identified RRCTs tested interventions with a short duration of action in a parallel open-label design. The study populations were large and clinical endpoints were, foremost, all-cause mortality and MI. A short intervention reduces the risk of crossover and enables a more reliable intention-to-treat analysis. Large sample sizes reduce the risk of an underpowered trial. Also the use of clinical endpoints facilitates the interpretation into routine care.
the quAlIty RegIstRy
The basis of the quality registry is the disease-specific collection of individualised patient data about Review medical interventions and outcomes. This information can be used to evaluate and compare the quality of care provided by participating units and assess implementation of guideline-based therapy. Typically, healthcare professionals have established the quality registries, 11 as seen in Sweden and the UK. SWEDE-HEART is one of over 100 national clinical quality registries in Sweden. It is publicly funded and collects information regarding clinically important variables concerning the whole chain of care in patients with MI. In SWEDEHEART, at each of 77 reporting centres, a dedicated nurse and doctor report data on patient characteristics and medication at time of admission to hospital and in-hospital treatments. Data are manually entered in an online case report form, whereupon they are anonymised. Up to 150 variables are collected in patients undergoing coronary angiography/ angioplasty. Internal monitoring by the registry holder shows a consistency of registry data with source data in the electronic health record of 96%. 12 Recently, automatic data transfer from the electronic patient record has been introduced in two centres, limiting the resources needed for data collection. Beyond the patient record, linkage to the National Cause of Death Registry, the National Patient Registry and the National Registry on Drug Prescriptions 12 enables access to data on adherence to drug interventions, readmission to hospital (future events) and vital status (see figure 1) .
stRengths of the RRct
The RRCT has several strengths when compared with the RCT (see box 1). Patient screening in traditional RCTs is often manual and therefore recruitment can be low. In RRCTs, online registration identifies patients eligible for inclusion, and in the case of the TASTE trial more than 50% of all patients with ST-elevation myocardial infarction referred for primary percutaneous coronary intervention were included. 7 Randomisation of interventions is undertaken via an online module embedded into the registry. The set-up is integrated in routine clinical care (as opposed to contracted core facilities) and therefore the informed consent process is incorporated into the clinical care setting. Although ethically distinct from the medical advice offered to patients, it is important to recognise that the treating physician is also an investigator. This integration into clinical routine is not unique in RRCTs and has been used in pragmatic RCTs in the past. 13 The study population in SWEDEHEART at present consists of more than 90% of all patients with MI in Sweden. In this way, by selecting patients from a national disease or treatment registry that covers nearly all patients, RRCTs have good external validity for the patient population.
14 Additionally, if a hard clinical outcome (as opposed to a complex and/ or surrogate endpoint) is chosen for an RRCT, there is limited need for endpoint adjudication [15] [16] [17] (also see table 1, Outcome column). Mortality is perhaps the only undisputed hard clinical endpoint-the disadvantage being its infrequent occurrence in many clinical settings, which entails a large sample size to avoid type II error. In RRCTs such as TASTE 15 and DETO2X trial, 16 the primary endpoint was mortality without adjudication. On the contrary, the VALIDATE trial had the composite endpoint of reinfarction and bleeding, which necessitated adjudication. Rigorous internal monitoring ensures that data captured in the patient record are also reflected in the SWEDEHEART registry. 12 Finally, the RRCT has been suggested to reduce costs by as much as 90% (in addition to the cost of the existing registry) of a traditional RCT design, 7 making it an attractive methodology for sponsors to choose, if access to a registry exists. Hence, through this integrated randomisation process of patients who are already part of an all-comer registry, the RRCT may collect vast quantities of baseline data and follow-up events Review at a low expense and with a high degree of generalisable results (see figure 2 ).
ethIcAl And legAl Aspects of the RRct
Both ethical and legal aspects separate the quality registry from the RRCT and the RCT (see table 2), and one must be aware of local and national guidelines and laws. 18 In Sweden, the patient data law and personal data act (based on Directive 95/46/EC) govern the handling of personal data. Patients provide informed consent such that anonymised data may form part of the quality registries. The patient data law allows patients the right to withdraw consent from the registry at any time and if so requires that all corresponding individual data be removed. In a clinical trial setting, this challenges Good Clinical Practice 19 given that trial data must be saved for future analysis and external audit trail by the sponsor or regulatory authorities. In practice, this has not been a major weakness. In the DETO2X trial none of the 6629 patients enrolled chose to withdraw consent for their anonymised data to enter the SWEDEHEART registry and thus part of the database for the trial. Of the 18 000 registered patients yearly in SWEDEHEART, only 2-3 patients per year withdraw consent. This, however, might be unique to the SWEDEHEART registry and stakeholders should be mindful of, and ascertain, the extent of missing cases.
RetestIng geneRIc dRugs
In recent years, the approach to cardiovascular care has seen that new health technologies and pharmacotherapies are often added to existing treatments. This approach raises concerns about escalating treatment costs and decreasing drug adherence. 20 Indeed, a concept of drug redundancy is emerging whereby the figure 1 An overview of the initiating patient event (myocardial infarction) and the data flow from nationwide Swedish registers through the randomised trial timeline. MI, myocardial infarction. 
Review
effectiveness of a historical pharmacotherapy is possibly weakened by the advent of newer agents added to a patient's treatment regimen.
The retesting of generic drugs for redundancy and/or repurposing using a traditional RCT approach is likely to be costly and logistically difficult. Moreover, it is unlikely that industry (who often retest phase II and III drugs that fail to show benefit for their originally assigned indication 21 ) would retest generic drugs because the return on financial investment is potentially very low. Thus, the strengths of the RRCT design could be ideal to this area of research. Examples of RRCTs exploring this concept include the recently started SPIRRIT-HFpEF RRCT, where investigators evaluate the efficacy of a generic aldosterone antagonist in patients with heart failure and preserved ejection fraction. 22 The recently completed VALIDATE-SWEDE-HEART RRCT showed equal efficacy of generic heparin when compared with bivalirudin in patients with acute MI undergoing coronary intervention, which has the potential to reduce annual healthcare costs in Sweden by about £5 million. 23 should the effectIveness of betA blockeRs In MI wIthout heARt fAIluRe be Retested?
Assuming therapeutic equipoise as the basis for re-evaluation of established therapies, 24 there is growing uncertainty as to the effectiveness of beta blockers for the management of MI without heart failure. 25 26 In the early 1980s, after a series of landmark trials, which showed improved outcomes and reduced mortality, beta blockers were approved for the treatment of MI. [27] [28] [29] However, these trials preceded the reperfusion era and enrolled mainly patients with large infarcts and/or heart failure. A systematic review of studies from the postreperfusion era found no net mortality benefit of long-term beta blockers therapy following MI. 30 This evidence is strengthened by contemporary registry data from the UK, which point to a non-beneficial survival effect of beta blockers in patients who survive MI and who have normal left ventricular function and no heart failure. 31 cAn the RRct plAtfoRM be used to test the effectIveness of betA blockeRs post-MI wIthout heARt fAIluRe?
To establish whether an RRCT design can be applied, several questions should be asked (see table 3 for summary). The first question is whether there is an existing registry with sufficient quality that it can be used for a clinical trial. Probing a quality registry with multiple questions regarding disease ascertainment (coverage), quality of data and losses to follow-up may uncover limitations that could endanger data quality in a clinical trial by introducing bias. A nationwide registry of MI could be considered an ideal platform for the conduction of a pragmatic A study may only use the data approved by the ethical review board. Additional data outputs may be possible but, require an amendment to the ethics approval.
Data in the registry can be modified, should there be corrupt or inaccurate data.
Data in the study database ought not to be changed after the clean file has been removed.
Changes to registry data are not required to be logged.
Changes to study data must be logged until the point at which the clean file is removed (audit trail).
Modified with permission from the Uppsala Clinical Research Center. Coverage in SWEDEHEART is almost 95%.
Is there sufficient uncertainty in clinical practice?
Meta-analyses, observational studies and guidelines do not give sufficient evidence for effectiveness in this patient group.
Is the intended intervention at phase IV or generic therapy?
Yes, generic therapy.
Do the intervention and the comparator constitute part of routine clinical care?
At present, patients with acute myocardial infarction and normal left ventricular function may be treated with either beta blockers and usual care or only usual care.
Is routine clinical care delivered according to its evidence base?
Yes.
Is it possible to set up a randomisation procedure as part of the quality registry?
Yes, the randomisation module is online and available at all hospitals participating in the SWEDEHEART network.
Do less controlled conditions create a safety issue?
No, beta blocker therapy has well known contraindications and its safety profile is established with more than 50 years' clinical experience.
Is there a network of hospitals which can facilitate a high rate of participant inclusion?
In total, 76 centres report to SWEDEHEART. A high proportion of these centres have previously participated in a SWEDEHEART RRCT.
Is the outcome of interest frequent and readily identified in clinical patient registries (and therefore clinically relevant)?
Swedish public registries and SWEDEHEART cover almost 100% mortality or subsequent myocardial infarction during follow-up.
Can minimal lost to follow-up be secured (through continuous follow-up in the clinical patient registries)?
Is there an interference with real-world practice during follow-up?
No, patients are otherwise treated according to guidelines-only the prescription of beta blockers and subsequent titration occurs.
Is trial arm crossover and the potential for equivalence acceptable?
Per-protocol analysis can be added to the intention-to-treat analysis.
Public funding for implementation of study findings?
Yes, this is an important clinical question that can potentially generate public funding for its implementation.
The questions may be used in conjunction with existing tools for pragmatic trial design, such as the PRECIS-2 tool. 48 RRCT, registry-based randomised clinical trial; SWEDEHEART, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies.
Review registry-based study on generic therapeutic interventions as described above with/without beta blockers post-MI. Of importance is patient safety in a clinical trial of long-term secondary prevention, especially in RRCTs with no additional structured follow-up of serious adverse events other than routine clinical visits. In the study of generic therapies, however, with more than 50 years of clinical routine with beta blockers, it is not unreasonable to believe that no new information will arise concerning serious adverse events in such a trial. Due to the large sample size needed in such a trial, the RRCT design might currently be the only available trial platform to address this clinically relevant question.
If there is no access to a registry, the questions listed in table 3 could serve as the basis for professional societies to engage with health legislators in an effort to establish registries for the purpose of assessing the healthcare quality and undertaking research obligations with potential clinical impact.
lIMItAtIons of the RRct desIgn
A precondition to perform an RRCT is the existence of a quality registry covering the population to be studied. 6 Whereas there is a tradition for these registries across Nordic countries, many others do not have this opportunity. The quality of data in an RRCT is bound by the quality of the data in the registry. In the Nordic countries and the UK, the validity of national registry data is generally considered to be high. Even so, an internal systematic review from a Norwegian endovascular registry showed that early deaths were under-reported by as much as 28%. 32 Indeed, concern over the quality of registry data is perhaps the main reluctance towards the RRCT framework for a clinical trial. 33 This highlights the need for regular audit of quality registry and the continued transparent reporting so that data in the RRCTs are complete and valid. Furthermore, stakeholders in primarily premarket drug efficacy testing have raised concern about safety issues concerning lack of structured follow-up and allowing for crossover between arms equalising the treatment effect. 34 Here, the balance between cost and trial design should be carefully weighed in any decision to use RRCTs, which may rely on interventions being tested in low-cost hospital units rather than contracted core facilities. The contrast between these choices can be highlighted with the example of drug adherence and possible crossover. In traditional RCTs, regular visits to the core facility, follow-up telephone calls and rigorous pill-counting measures are instituted to ensure high levels of adherence to determine the explanatory drug efficacy. In the pragmatic RRCT, where an effectiveness measure is sought, adherence is encouraged through routine doctor-patient encounters in-hospital and during follow-up, and no additional visits other than routine care are scheduled. In the SPIRRIT trial, a definition suitable for this type of pragmatic clinical trial has been adopted, 22 whereby data from the prescription registry are evaluated to determine whether 'written' (electronic) prescriptions were continuously renewed and collected by the patient, indicating drug adherence. Another important challenge for the RRCT is the capture of clinical endpoints. If endpoints are chosen that are not readily sampled by the registry, this could lead to risk of type II error, that is an abnormal low event rate and the failure to detect a true effect. In the case of a 'negative' RRCT, weight should be given to analysis of the capture of events and the estimated event rate. Beforehand, consideration should be made with regard to sample size and follow-up time to account for potential under-reporting of events. Indeed, event-driven trials could help mitigate this weakness.
It is important to acknowledge that reclassification of only a small number of events may change the result of a trial and the lack of adjudication in RRCTs should merit consideration. This is important if events are classified by use of the International Classification of Diseases (ICD) codes or cause of death through public registries. External validation has shown that consistency is at most moderate for some events, such as death due to stroke, 35 while at the same time high for diagnoses such as admission due to heart failure. 36 It should be emphasised that the reporting of MI in the SWEDEHEART registry is not based on ICD codes, but reported by dedicated doctors with reference to the registry manual. Should there be need to examine endpoints that are less likely to appear in public registries (such as minor bleeding events), a hybridisation model may be chosen to ensure adequate capture and validation of endpoints. 17 That said, such addition of structured follow-up and adjudication committee to the RRCT will of course increase the trial costs.
goIng foRwARd wIth RRcts
For the RRCT concept to expand to drug development trials, stakeholders from the pharmaceutical industry 37 have highlighted the need for greater stringency and clarification. Yet a balance must be acknowledged between rigorous and expensive RCTs and informative, but less stringent RRCTs. At present, there is no clear definition of the RRCT, and it is difficult to identify if trials are based on the RRCT methodology of quality registries or simply incorporate public registry data for event capture. A revision of the Consolidated Standards of Reporting Trials guidelines to include information about the conduct and reporting of RRCTs may facilitate the design and implementation of clinical trials based on this concept that, due to the high costs of RCTs, would otherwise not be conducted. 33 38 Going forward, the combination of the RRCT with the adaptive trial 39 to make the 'adaptive RRCT' offers the promise of combining efficiency at scale with the modification of trial parameters in accord with real-time observations.
conclusIon
In the contemporary era, bringing forward new drugs is constrained by cumbersome administrative procedures and escalating costs. Beyond safety and efficacy testing, a demand for value (against existing drugs) generates non-inferiority testing that necessitates huge sample sizes with increasing trial complexity and additional resources. Moreover, drug efficacy testing RCTs are hampered by their lack of generalisability and, in the search for 'positive' results, the use of composite endpoints and prolonged follow-up may hinder the speed at which new drugs are brought to market. Nowadays, there is compelling societal need for a change in trial design that relates to enabling lower overall national healthcare costs. When introduced to market, drugs are often used off-label in a broad heterogeneous patient population for which the drug might be useful, due to a lack of postmarket effectiveness testing. This may lead to drug redundancy and patient adherence trade-off to multiple therapies. Therefore, retesting generic drugs in a pragmatic effectiveness setting could prove valuable in reducing healthcare cost and improving population health. As an example, the clinical effectiveness of beta blockers in patients with MI and a normal ejection fraction is now in need of clarification. Building on assets of public nationwide quality registries, the RRCT fuses random sampling and pragmatic trial design in a new robust framework for inexpensive, clinically relevant trials. While the use of national registries in
